Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

Elisabeth Paietta

doi:10.1016/j.clml.2015.02.009

Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

Elisabeth Paietta

Oncology

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Abstract

Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.

Original language	English (US)
Article number	548
Pages (from-to)	S2-S6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	15
Issue number	S
DOIs	https://doi.org/10.1016/j.clml.2015.02.009
State	Published - Jun 1 2015

Keywords

Acute leukemias
MRD
Response definition

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2015.02.009

Cite this

@article{7331048e8507439b8ec08888655120c4,

title = "Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?",

abstract = "Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.",

keywords = "Acute leukemias, MRD, Response definition",

author = "Elisabeth Paietta",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.clml.2015.02.009",

language = "English (US)",

volume = "15",

pages = "S2--S6",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "S",

}

TY - JOUR

T1 - Minimal Residual Disease in AML

T2 - Why Has It Lagged Behind Pediatric ALL?

AU - Paietta, Elisabeth

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.

AB - Although the concept of minimal residual disease (MRD) as an indicator for the quality of treatment response is the same in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), the practice of measuring MRD levels for monitoring response and guiding therapy after induction has been implemented much more rapidly in ALL, particularly pediatric ALL, than in AML. In this perspective we examine the facts and discuss why ALL appears to be more amenable to MRD-shaped risk allocation and a revised definition of complete remission.

KW - Acute leukemias

KW - MRD

KW - Response definition

UR - http://www.scopus.com/inward/record.url?scp=84939629912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939629912&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2015.02.009

DO - 10.1016/j.clml.2015.02.009

M3 - Comment/debate

C2 - 26297274

AN - SCOPUS:84939629912

SN - 2152-2650

VL - 15

SP - S2-S6

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - S

M1 - 548

ER -

Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this